NCT05641272View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

December 1, 2026

Conditions
Allergic RhinitisAllergic AsthmaAllergic RhinoconjunctivitisAllergy to House Dust Mite
Interventions
BIOLOGICAL

3,000 MM09

Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 3.000 UTm/mL for sublingual immunotherapy.

BIOLOGICAL

9,000 MM09

Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 9.000 UTm/mL for sublingual immunotherapy.

OTHER

Placebo sublingual

The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.

Trial Locations (1)

2035

Fundación CIDEA, Buenos Aires

Sponsors

Lead Sponsor

Inmunotek S.L.

Collaborators (1)

LAT Research
All Listed Sponsors
collaborator

LAT Research

OTHER

collaborator

Xolomon Tree S.L.

UNKNOWN

lead

Inmunotek S.L.

INDUSTRY

NCT05641272 - Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract | Biotech Hunter | Biotech Hunter